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Background: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as
first-line treatment in patients with metastatic colorectal cancer.
Methods: Patients previously untreated for metastatic disease were randomized in: group A (irinotecan,
capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab) and group B (irinotecan, leucovorin, fluorouracil,
bevacizumab, every 2 weeks; FOLFIRI-bevacizumab). Primary endpoint was progression-free survival (PFS). Plasma
concentrations of nitric oxide, osteopontin, TGF-β1 and VEGF-A were measured at baseline and during treatment.
Results: Among 285 eligible patients, 143 were randomized to group A and 142 to group B. Fifty-five patients
(38.5%) in group A and 57 (40.1%) in group B responded (p = 0.81). After a median follow-up of 42 months, median
PFS was 10.2 and 10.8 months (p = 0.74), while median OS was 20.0 and 25.3 months (p = 0.099), for groups A and
B, respectively. Most frequent grade 3–4 toxicities (group A vs group B) were neutropenia (13% vs 22%, p = 0.053)
and diarrhea (19% vs 11%, p = 0.082). Baseline plasma osteopontin concentrations demonstrated prognostic
significance for both PFS and OS.
Conclusions: This trial did not show significant differences in efficacy between the groups. However, the toxicity
profile was different. Baseline plasma osteopontin concentrations demonstrated independent prognostic
significance. (Registration number: ACTRN12610000270011)
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Colorectal cancer (CRC) is the third leading cause of can-
cer and cancer death in the US. Approximately, 15–20%
of the patients have stage IV disease at diagnosis. Progno-
sis of this group of patients is poor, as only less than 10%
of patients survive beyond 5 years. The introduction of
new drugs in the systemic treatment of metastatic CRC
(mCRC) during the last two decades has increased median
survival in clinical trials from 6–9 months to beyond
2 years [1].
Irinotecan combined with 5-fluorouracil (5-FU)-based
chemotherapy and bevacizumab (Bev) consist an estab-
lished option in the treatment of mCRC [1]. Continuous
infusion of 5-FU added to irinotecan (FOLFIRI) has been
shown to be more effective and tolerable than bolus 5-FU
[2]. However, this regimen requires hospitalization or the
placement of central venous line. In contrast, the
irinotecan-capecitabine combination (XELIRI) appears to
be more convenient [2]. In the BICC-C randomized trial,
XELIRI, compared with FOLFIRI, was associated with
higher rates of serious nausea, vomiting, diarrhea, dehy-
dration, hand-foot syndrome and treatment discontinu-
ation. Also, progression-free survival was shorter in
patients treated with XELIRI, when only patients, who
completed treatment, were compared [2]. As a result, the
XELIRI arm was discontinued before treatment amend-
ment with the inclusion of Bev. Therefore, no comparison
of FOLFIRI versus XELIRI combined with Bev exists in
the literature.
On the other hand, although recent research has
revealed a number of valuable predictive biomarkers of
the efficacy of epidermal growth factor inhibitors, no
such progress has been made with regard to the treat-
ment with Bev [3].
The aim of the study was to compare the efficacy and
toxicity of XELIRI vs FOLFIRI both combined with Bev
in the treatment of mCRC. Also, angiogenic biomarkers
were measured in the plasma of patients included in the




In this multicenter prospective randomized phase III
trial, patients with stage IV CRC, previously untreated
for metastatic disease, were enrolled. All patients had
histologically or cytologically confirmed mCRC and two-
dimensional measurable disease, with at least one lesion
being ≥15 mm. Previous adjuvant or neoadjuvant
chemotherapy should had been completed at least
4 months before enrollment and prior major surgery or
radiotherapy 4 weeks before enrollment. Age was
≥18 years with performance status (PS) 0–2 (ECOG) and
adequate bone marrow, renal and liver function.The clinical protocol was approved by Institutional Re-
view Boards (IRBs) in participating institutions and by
the National Organization for Medicines. The trial was
included in the Australian New Zealand Clinical Trials
Registry (ANZCTR) and allocated the following Regis-
tration Number: ACTRN12610000270011. The transla-
tional research protocol was approved by the Bioethics
Committee of the Aristotle University of Thessaloniki.
All patients provided study specific written informed
consent. In addition, patients who were willing to pro-
vide biological material for future translational research
studies signed a separate informed consent.
Treatment
Patients were randomly assigned to receive Bev 7.5 mg/
Kg day 1, irinotecan 240 mg/m2 day 1 and capecitabine
1000 mg/m2 days 1–14 repeated every 21 days for 6
cycles (group A, XELIRI) or Bev 5 mg/Kg day 1, irinote-
can 180 mg/m2 day 1, leucovorin 200 mg/m2 2 h infu-
sion day 1, 5-FU 400 mg/m2 IV bolus day 1 followed by
a 5-FU 2,400 mg/m2 46 h continuous infusion repeated
every 14 days for 12 cycles (group B, FOLFIRI). Bev was
not to be administered to patients who had a contraindi-
cation and optionally in elderly individuals who were
more than 75 years old. During randomization, done
centrally at the HeCOG Data Office, patients were strati-
fied according to performance status (PS ECOG 0 vs 1–
2), the presence or not of liver metastases and previous
administration or not of adjuvant chemotherapy.
All adverse events were estimated according to the
NCI CTC 3.0 grading scale. The next cycle was not
administered unless the granulocyte number was
≥1,500/mm³, platelet number ≥100,000/mm³, and all
non-hematological toxicities resolved to grade ≤1. In
case of a 2-week delay, treatment could be inter-
rupted, according to the investigator’s decision.
Capecitabine was interrupted in case of hand-foot
syndrome, mucositis and diarrhea grade 2, until toxi-
cities resolved. The doses of capecitabine that had
been omitted were not given at a later point. Admin-
istration of G-CSF and recombinant erythropoietin
was allowed. Also, oral pyridoxine was allowed, admi-
nistered as prophylaxis or the treatment of existing
hand-foot syndrome.
Evaluation of disease
Disease evaluation was carried out after 3 cycles of treat-
ment in group A and after 6 cycles in group B, at the
end of treatment, and every 3 months thereafter by chest
X-rays and CT scans of the abdomen and pelvis. MRI or
bone scan were allowed when indicated. Objective re-
sponse classification was based on the RECIST 1.0
guidelines. No central review of the imaging material
was done.
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Nine milliliters (mL) of blood were collected in EDTA
tubes, in the morning (between 08.30 and 11.00 h), from
173 patients with mCRC before the initiation of the
treatment (baseline sample) and from 51 patients during
the antiangiogenic treatment with Bev (on-treatment
sample, at least 3 weeks after treatment initiation). The
plasma was separated by centrifugation (at 2,000 rpm)
and aliquoted and frozen in −80 °C within 20 min from
blood collection.
Plasma concentrations of nitric oxide (NO), osteopon-
tin (OPN), transforming growth factor beta 1 (TGF-β1)
and vascular endothelial growth factor A (VEGF-A) were
measured, in duplicate, by solid-phase enzyme-linked
immunosorbent (ELISA) assays using commercially
available kits (VEGF-A from R&D Systems, Minneapolis,
MN and the rest from Assay Designs, Ann Arbor, MI).
Paired baseline samples and on-treatment samples from
the same patient were run in the same ELISA plate for
direct comparison. Due to the transient and volatile na-
ture of NO, the assay used estimated NO blood levels by
measuring its two stable breakdown products, nitrate






Randomized to A but received B n=3 
Never started treatment n=5 
Lost medical records n=1
Completed treatment (6 cycles) n=88 
Discontinued treatment n=49 
Death n=5 
Toxicity (non fatal) n=20 
Disease progression n=11 
Moved to another hospital n=3 




Lost to follow-up n=2 
Still on follow-up n=37
Figure 1 Consort diagram: Among 285 eligible patients 143 were rand
In group A 88 (61%) and in group B 89 (63%) of the patients completed tre
disease progression and doctor’s or patient’s decision. Discontinuation ratephotometric means. The lower limit of detection was
3.13 μmol/L for the NO assay, 2.00 ng/mL for OPN,
31.20 pg/mL for TGF-β1, and 15.60 pg/mL for the
VEGF-A assay. All assays were specific without signifi-
cant cross-reactivity with other related molecules. The
intra- and inter-assay coefficients of variation, estab-
lished by the manufacturers for concentrations close to
the center of the standard curves, were 3.1% and 4.2%
for the NO assay, 3.7% and 9.2% for OPN, 6.1% and
12.3% for TGF-β1, and 4.5% and 7.0% for the VEGF-A
assay, respectively.
Statistical analysis
The primary endpoint of the study was to compare
progression-free survival (PFS) between the two treat-
ment schedules, while secondary endpoints were object-
ive response rate (ORR), overall survival (OS) and the
toxicity profile of the two groups of treatment, as well as
the prognostic significance of the evaluated angiogenic
markers. A sample of 300 patients was required for the
study, to ensure an 80% power at the 5% level of signifi-
cance, for a two-sided test of the hypothesis that a differ-






Randomized to B but received A n=4 
Never started treatment n=6 
Lost medical records n=1
Completed treatment (12 cycles) n=89
Discontinued treatment n=46
Death n=4 
Toxicity (non fatal) n=6 
Doctor’s decision n=1 
Disease progression n=18
Voluntary withdrawal n=8 




Lost to follow-up n=6 
Still on follow-up n=42
omized in group A (XELIRI-Bev) and 142 in group B (FOLFIRI-Bev).
atment. Reasons of discontinuation were death, non-fatal toxicity,
s did not differ between the two groups (p = 0.80).
Table 1 Selected basic patient characteristics*




Median (range) 66 (28–84) 66 (32–80)
N (%) N (%)
<60 40 (28) 44 (31)
≥60 103 (72) 98 (69)
Gender
Male 79 (55) 92 (65)
Female 64 (45) 50 (35)
PS (ECOG)
0 92 (64) 94 (66)
1 37 (26) 40 (28)
2 12 (8) 6 (4)
Missing data 2 (2) 2 (2)
Primary location
Colon 98 (68) 85 (60)
Rectum 35 (25) 44 (31)
Rectosigmoid 3 (2) 8 (6)
Rectosigmoid and cecum 1 (1) –
Misssing data 6 (4) 5 (3)
Stage at diagnosis
I 2 (1) 3 (2)
II 5 (4) 11 (8)
III 23 (16) 26 (18)
IV 107 (75) 90 (63)
Missing data 6 (4) 12 (9)
Previous adjuvant chemotherapy
No 114 (80) 112 (79)
Yes 27 (19) 27 (19)
Missing data 2 (1) 3 (2)
Previous surgery 114 (80) 123 (87)
Symptomatic disease
Yes 70 (49) 66 (46)
No 56 (39) 54 (38)
Missing data 17 (12) 22 (16)
Organs involved
Liver 103 (72) 101 (71)
Lung 51 (36) 39 (28)
Other 54 (38) 61 (43)
Table 1 Selected basic patient characteristics* (Continued)
Number of organs involved
1 84 (59) 85 (60)
2 39 (27) 43 (30)
≥3 19 (13) 14 (10)
Missing data 1 (1) –
*Pearson chi-square and Fisher’s exact tests were applied to compare patient
characteristics (all p values above 0.05).
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patients needed to enter the study. The study was not
terminated prematurely at the planned interim analysis,
which was performed when 50% of the endpoints had
been reached.
Pearson chi-square and Fisher’s exact tests were ap-
plied to compare patient characteristics, response and
toxicity. The Wilcoxon signed rank test was used for
comparison between baseline and on-treatment plasma
concentrations. The Mann–Whitney test was used to
evaluate differences in the distribution of baseline values
or in the percent change (on-treatment sample value
minus baseline value divided by the baseline value times
100) according to overall response.
PFS was calculated from the randomization date to the
first progression of the disease or death from any cause.
OS was calculated from the date of randomization to the
date of death or last follow-up. The Kaplan-Meier
method was used to estimate PFS, median follow-up and
OS distributions, while the log-rank test was used to
compare these distributions. PFS, OS and ORR were
analyzed on an intent-to-treat basis, while in the safety
analysis and the description of treatment characteristics
only the treated population was included.
The median cut-off for all evaluated markers was used
to dichotomize plasma concentrations into low and high.
Cox proportional hazard regression analyses, adjusted
for treatment, were performed for selected clinicopatho-
logical characteristics and plasma concentrations of mar-
kers to assess prognostic significance on OS and PFS.
Multivariate analysis was performed in the subpopula-
tion of Bev treated patients. A backward selection pro-
cedure, based on the likelihood ratio statistic with a
removal criterion p> 0.10, was used to determine the
final model. This procedure begins by fitting a model
with all the variables of interest and then, at each step,
the variable showing the smallest contribution to the
model is deleted until all the variables remaining in the
model are significant at the p< 0.10 level. This proced-
ure identified a subclass of significant variables among
the following: treatment group (FOLFIRI vs XELIRI),
age (≥60 vs <60), sex (women vs men), PS (1–2 vs 0),
adjuvant chemotherapy (yes vs no), primary site (rectal
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NO, OPN, TGF-β1 and VEGF-A plasma concentrations
(high vs low). Data were analyzed using SPSS for Win-
dows version 15 (SPSS Inc., Chicago, IL).
Results
Between January 24, 2006, and January 21, 2008, 302
patients were enrolled in the study. Among them, 285
patients (94%) were eligible, 143 were randomized to
group A and 142 to group B. The consort diagram for
the patient population is illustrated in Figure 1. Table 1
shows the baseline characteristics of all eligible patients.
There were no statistically significant differences in
baseline characteristics between the two groups.
Treatment
Treatment and toxicity data are presented for the patients
as treated, in contrast to the response and survival data
and the consort diagram where the patient population is
presented as randomized. In group A, 138 patients
received 635 cycles of XELIRI (median, 6; range, 1–6) and
in group B, 134 patients received 1,324 cycles of FOLFIRI
(median, 12; range, 1–12). Among them, 89 patients (65%)
completed treatment with XELIRI and 86 patients (64%)
with FOLFIRI. In total, in group A, 42 patients (30%) and
50 patients (36%) required a dose reduction of irinotecan
and capecitabine, respectively. In group B, 41 patients
(31%) and 43 patients (32%) required a dose reduction of
irinotecan and 5-FU, respectively. The number of cycles
delivered at full dose was 472 (74%) in group A and 958
(72%) in group B. Median relative dose intensities in
group A were 0.94 (range, 0.44–1.32) for irinotecan and
0.56 (range, 0.06–1.06) for capecitabine, while in group B
dose intensities were 0.90 (range, 0.37–1.39) for irinote-
can, 0.94 (range, 0.41–1.94) for bolus 5-FU and 0.90
(range, 0.31–1.08) for the 5-FU continuous infusion. Bev
was administered in 237 (87%) of the patients (117 inFigure 2 Kaplan-Meier curves for survival (left) and PFS (right) accordgroup A and 120 in group B). The reasons of not adminis-
tering Bev in 35 of the 272 treated patients were: a history
of deep vein thrombosis (2), severe coronary artery disease
(3), inadequately controlled arterial hypertension (13),
other significant cardiac diseases (3), stroke (1), recent
metastasectomy (1), brain metastasis with edema (1),
advanced age (6), patient’s decision (1) and unknown rea-
sons (4). In total, 64 patients in group A and 46 in group
B received Bev as maintenance for a median of 4 cycles
(range, 1–35) and 6 cycles (range, 2–48), respectively.
Advanced age patients that did not receive Bev were
balanced between groups: in group A, 3 out of 16 patients
and in group B, 3 out of 17 patients aged >75 years did
not receive Bev.
Response
In group A, 55 patients (38.5%) achieved an objective re-
sponse (complete response, 3.5%; partial response, 35%),
30 patients (21%) had stable disease and 15 (10.5%) pro-
gressive disease. In group B, 57 patients (40.1%) responded
(complete response, 2.8%; partial response, 37.3%), 41
patients (28.9%) had stable disease and 16 (11.3%) pro-
gressive disease. Overall response rate did not differ sig-
nificantly between the two groups (p= 0.81). In group A,
43 patients (30.1%) were not evaluated for response be-
cause of treatment discontinuation (24 patients, 16.8%),
early death (5, 3.5%), missing data (3, 2.1%), or non-
evaluable disease (11, 7.7%). In group B, 28 patients
(19.7%) were not evaluated for response because of treat-
ment discontinuation (5 patients, 3.5%), early death (2,
1.4%), or non-evaluable disease (21, 14.8%).
Survival
After a median follow-up of 42 months (range 0.4–55.4),
93 patients (65%) progressed and 104 (73%) died in
group A, while 109 patients (77%) progressed and 94
(66%) died in group B. Median PFS was 10.2 monthsing to treatment allocation.
Table 2 Severe toxicity per treatment group (as treated population)*
Group A Group B
(XELIRI-Bev) (FOLFIRI-Bev)
N= 133 N=132
Grade III Grade IV Grade III Grade IV
N % N % N % N %
Anemia – – – – 1 1 1 1
Leucopenia 8 6 1 1 5 4 – –
Neutropenia 11 8 6 5 25 19 4 3
Febrile Neutropenia 2 2 2 2 2 2 – –
Thrombocytopenia – – 1 1 – – – –
Infection – – – – 2 2 – –
Fever 2 2 – – – – – –
Fatigue 3 2 – – 3 2 – –
Anorexia – – – – 2 2 – –
Nausea 1 1 – – – – – –
Vomiting1 7 5 – – – – – –
Mucositis 1 1 – – 2 2 – –
Diarrhea 24 18 1 1 14 11 – –
Other gastrointestinal – – – – 1 1 – –
Cholinergic syndrome – – – – 1 1 – –
Hiccups 1 1 – – – – – –
Voice changes 1 1 – – – – – –
Transaminasemia 3 2 – – 1 1 – –
Hand–foot syndrome 1 1 – – 1 1 – –
Metabolic 3 2 1 1 4 3 2 2
Allergic reaction 1 1 – – – – – –
Electrolyte disturbances 7 5 – – 7 5 1 1
Hypertension 6 5 – – 5 4 – –
Thrombosis 4 3 – – 5 4 2 2
Pulmonary embolism – – – – – – 1 1
Syncope 1 1 – – 5 4 – –
Cardiac 1 1 1 1 1 1 2 2
Hemorrhage – – – – 1 1 – –
*Pearson chi-square and Fisher’s exact tests were applied to compare severe toxicities (all p values above 0.05, except for vomiting).
1Fisher’s exact test, p = 0.014.
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10.8 months (95% CI: 9.7–11.8) in group B (p = 0.74).
Median OS was 20 months (95% CI: 15.4–24.6) in group
A and 25.3 months (95% CI: 22.1–28.6) in group B
(p = 0.099). Two-year PFS and OS rates were 18% and
44% in group A, and 17% and 54% in group B, respect-
ively. Kaplan-Meier curves for OS and PFS according to
treatment are shown in Figure 2.
Toxicity
Grade 3–4 adverse events are shown in Table 2. The
most common (group A vs group B) were neutropenia(13% vs 22%, Fisher’s exact test, p = 0.053) and diarrhea
(19% vs 11%, Fisher’s exact test, p = 0.082). Vomiting was
more frequent with XELIRI (5% vs 0%, Fisher’s exact
test, p = 0.014). As for the Bev-treated patients most
common serious toxicities were hypertension and
thrombosis. Pulmonary embolism occurred only in one
patient. No treatment-related deaths were recorded.
Translational research
Baseline plasma samples were collected from 200 patients.
Among them, 59 also had an on-treatment plasma sample
(at least 3 weeks after treatment initiation). Twenty-seven
Table 3 Descriptive characteristics for evaluated plasma markers
N Mean Median SD Min Max Wilcoxon’s p
NO (μmol/L)
Baseline samples 173 261.47 211.80 192.86 8.28 1,567.20 0.89
On-treatment samples* 51 237.09 227.10 140.68 42.69 606.70
OPN (ng/mL)
Baseline samples 173 98.68 62.56 89.29 23.12 512.00 0.002
On-treatment samples 51 75.42 54.72 76.32 25.44 507.52
TGF-β1(ng/mL)
Baseline samples 173 34.24 20.63 57.07 0.53 662.21 0.025
On-treatment samples 51 28.36 18.80 33.35 3.34 228.33
VEGF-A (pg/mL)
Baseline samples 172 122.54 57.85 190.33 15.60 1,601.31 <0.001
On-treatment samples 51 46.79 44.80 21.17 15.60 130.81
N, number; SD, standard deviation; Min, minimum level detected; Max, maximum level detected.
*On-treatment samples, at least 3 weeks after treatment initiation.
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not receive Bev. Hence, 173 baseline and 51 on-treatment
samples were evaluated in the analysis.
Plasma concentrations of all markers, including mean,
median, minimum and maximun values, are shown in
Table 3. Plasma levels of OPN, TGF-β1 and VEGF-A
were significantly reduced during treatment (Wilcoxon’s
test, p = 0.002, p = 0.025 and p< 0.001, respectively).
Interestingly, this was not associated with response, ex-
cept for TGF-β1, for which a significantly greater per-
cent change was seen in responders versus non-
responders (Mann–Whitney test, p = 0.012). It appears
that treatment might had affected plasma concentrations
of most of the markers, regardless of the type of re-
sponse exhibited by the patients. In addition, baseline
plasma levels of markers did not predict response.Low OPN 
High OPN 
Figure 3 High baseline plasma OPN concentrations (above the mediaIn univariate analysis, the prognostic significance of in-
creasing baseline plasma concentrations (used as a con-
tinuous variable) of most markers was prominent.
Increasing baseline plasma concentrations of NO were
significantly associated with shorter PFS (Hazard ration
[HR] = 1.001, 95% CI: 1.001–1.002, p = 0.012) and OS
(HR= 1.001, 95% CI: 1.001–1.002, p = 0.002). Also, in-
creasing baseline plasma concentrations of OPN were
associated with shorter PFS (HR= 1.006, 95% CI: 1.003–
1.008, p< 0.001) and OS (HR= 1.008, 95% CI: 1.006–
1.010, p< 0.001). Finally, increasing baseline plasma
concentrations of VEGF-A were associated with adverse
prognosis for OS (HR= 1.001, 95% CI: 1.000–1.002,
p = 0.020). In addition, high baseline plasma OPN
concentrations (above the median) were of adverse
prognostic value for PFS (HR= 1.701, 95% CI: 1.229–n) were significantly associated with shorter OS and PFS.
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3.000, p< 0.001), as shown in Figure 3. In multivariate
analysis, as shown in Table 4, only high baseline plasma
OPN concentrations demonstrated prognostic signifi-
cance, for both PFS and OS, independently of treatment
group, PS and number of organs involved. Similar results
were observed when continuous values of plasma
markers were included in the model.
Discussion
In the present randomized phase III trial, the primary
endpoint, PFS, was comparable between the two treat-
ment groups. Patients assigned to the XELIRI-Bev group
had a median PFS of 10.2 months and those assigned to
the FOLFIRI-Bev group 10.8 months. In contrast, in the
BICC-C randomized trial [2], patients treated with FOL-
FIRI presented with a significantly longer PFS compared
with those treated with XELIRI. Also, in the EORTC
randomized trial [4], treatment with FOLFIRI resulted in
a better PFS and OS than that with XELIRI, but the ana-
lysis included only 85 patients, due to the early termin-
ation of the trial and therefore no definitive conclusions
could be made.
However, data regarding XELIRI combined with Bev
are scarce in the literature. Most studies published in full
paper form are retrospective in nature [5-7], with only
Moehler et al. [8] recently reporting the results of a
phase II trial. In the above studies, the major serious
toxicities were diarrhea in 15–18% of the patients, nau-
sea/vomiting in 3–7% and neutropenia in 6–7%. Doses
were reduced in 31–62% of the patients, while treatment
was interrupted due to toxicity in 11–18% of the patients.Table 4 Multivariate Cox regression analysis (in the subpopul
Overall survival
HR 95% CI Wald
Group
XELIRI-Bev 1
FOLFIRI-Bev 0.842 0.587–1.207 0.35
Performance status
0 1
1–2 1.710 1.164–2.513 0.006
Number of organs involved
1 1
2 1.580 1.052–2.373 0.027
≥3 2.598 1.502–4.493 0.001
Osteopontin (OPN)
Low 1
High 1.632 1.116–2.387 0.012
*Both models remain the same whether continuous or binary variables of plasma c
HR, hazard ratio; CI, confidence interval.No treatment related deaths occurred. In the FNCLCC
ACCORD 13/0503 randomized non-comparative study
[9], the most frequent grade 3–4 events in patients treated
with XELIRI-Bev were neutropenia (18%), asthenia (14%),
diarrhea (12%), vomiting (7%) and hand-foot syndrome
(6%). However, a lower than usual dose of irinotecan was
administered (200 mg/m2).
In contrast, in the BICC-C trial [2], the incidence of
the most prominent grade 3–4 adverse events with
XELIRI was much higher: diarrhea (47%), neutropenia
(32%), dehydration (19%), nausea (18%) and vomiting
(16%). Twenty-five percent of the patients discontinued
the regimen and the treatment was prematurely termi-
nated. In the CAIRO trial [10], patients assigned to the
XELIRI (combination) arm presented more frequently
with diarrhea (27%), nausea-vomiting (9%), neutropenia
(7%), febrile neutropenia (7%) and hand-foot syndrome
(7%), as grade 3–4 toxicities. Also, in the EORTC 40015
study [4], patients treated with XELIRI demonstrated
high rates of grade 3–4 toxicities: diarrhea (37%), neu-
tropenia (14%), vomiting (7%) and nausea (4%). Fifty-
three percent of the patients needed dose reduction and
14% succumbed from toxicity. It seems however, that
more recent XELIRI studies present lower rates of ser-
ious toxicities. One possible explanation could be that
there is now more experience with this regimen and
patients are more efficiently instructed and managed. In
the present phase III study, serious adverse events were
relatively less frequent and only 15% of our patients dis-
continued treatment due to toxicity.
Among the above-mentioned studies with XELIRI-Bev,
only a few [5,8,9] included previously untreated foration of Bev-treated patients)*
Progression-free survival










oncentrations of markers were used.
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67%, PFS was 12–13 months and OS 24 months. These
results were slightly better than ours, but it should be
mentioned that they are derived from phase II studies.
The toxicity of the systemic treatment for CRC, in com-
bination with the high cost, necessitates the discovery of
predictive biomarkers of response.
Angiogenesis is necessary for cancer progression and
constitutes a complex process with many different co-
operating pathways, where VEGF-A, NO and TGF-β
seem to have an important role. Early studies have
demonstrated that immunohistochemical expression and
high serum levels of VEGF-A and TGF-β1 are associated
with adverse prognosis in CRC patients [11-17]. In con-
trast, the significance of NO blood levels in these
patients is controversial [18,19]. In the present study, the
first to evaluate plasma levels of the above molecules in
Bev-treated mCRC patients, none of them was found to
be associated with prognosis. However, in a recent study,
baseline plasma levels of interleukin-8 were correlated
with short PFS, while a number of other circulating
angiogenic biomarkers, such as basic fibroblast growth
factor, placental growth factor, hepatocyte growth factor,
stromal-derived factor-1 and macrophage chemoattract-
ant protein-3 were increased before the radiographic de-
velopment of progressive disease in CRC patients
treated with FOLFIRI-Bev [20].
Finally, OPN is a glycoprotein, which seems to in-
duce cellular proliferation, survival, metastasis and
angiogenesis [21]. More precisely, it is a soluble,
secreted protein that can act as an autocrine and para-
crine factor, as well as a modulator of cell adhesion
through its interaction with integrins and CD44. It
promotes multiple steps of cancer progression, such as
cellular adhesion, proliferation, invasion, extracellular
matrix degradation and metastasis, cancer immunoto-
lerance and angiogenesis [21]. In CRC, OPN expres-
sion is proportionately increased with tumor stage and
seems to be of adverse prognostic significance [22-26].
There are limited data in the literature with regard to
circulating OPN in the blood of patients with colorec-
tal cancer [27] and none, to our knowledge, with re-
gard to a possible prognostic or predictive value of
circulating OPN in CRC patients. In the present study,
baseline plasma OPN concentrations were reduced
with antiangiogenic treatment, while patients with low
baseline plasma OPN levels had a significantly longer
PFS and OS independently of other well-established
prognostic factors, such as performance status and the
number of organs involved. OPN measurements in
plasma could therefore provide valuable prognostic in-
formation, which is robust, accurate and easily deter-
mined with a relatively low cost compared to other
methods, which require adequate tumor tissue.Conclusions
In conclusion, in this trial no significant differences were
demonstrated in efficacy between the two groups. How-
ever, the toxicity profile was different. Baseline plasma
osteopontin concentrations demonstrated independent
prognostic significance. Further studies are warranted to
validate the prognostic value of OPN in independent
cohorts of colorectal cancer patients.
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